• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 24, 2014

View Archived Issues

In the clinic

Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., said the protocol for its phase II study of the mechanism of action of PH-10 in psoriasis is now available on www.clinicaltrials.gov. Read More

Other news to note

Ariad Pharmaceuticals Inc., of Cambridge, Mass., and Otsuka Pharmaceutical Co. Ltd., of Tokyo, said they entered an agreement for Otsuka to commercialize Ariad's Iclusig (ponatinib) in Japan and nine other Asian countries and to fund future clinical trials in those regions. Read More

Financings

Lion Biotechnologies Inc., of Los Angeles, said it closed its underwritten offering of 6 million shares priced at $5.75 apiece, including 782,608 shares to cover the full overallotment option. Gross proceeds totaled $34.5 million. Read More

News from Washington

The Department of Justice (DoJ) filed a civil False Claims Act complaint, in conjunction with two whistleblower actions, against Omnicare Inc., of Crystal, Minn., alleging that the pharmaceuticals provider solicited and received millions of dollars in kickbacks from Abbott, of Abbott Park, Ill., in exchange for purchasing and recommending anticonvulsant drug Depakote (valproic acid) for controlling dementia patients in nursing homes it serviced. Read More

Holiday Notice

BioWorld's offices will be closed Thursday, Dec. 25, in observance of the Christmas Day holiday in the U.S. Read More

Eddingpharm moves into CDV, licenses Brinavess from Cardiome Pharma

SHANGHAI – Eddingpharm Co. Ltd. will develop and commercialize Cardiome Pharma Corp.'s atrial fibrillation drug, Brinavess (vernakalant), paying $1 million up front for the Greater China rights with potential for the Vancouver, British Columbia-based Cardiome to receive $3 million more in regulatory milestone payments. Read More

Argentina and Cuba join forces to rev up biotech development

BOGOTA, Colombia – The National Council of Genetic Engineering of Cuba (CIGB) and the National Council of Technical and Scientific Researches of Argentina (Conicet) have agreed to team up for the development of new biotech products. Read More

Will the new U.S.-Cuba dynamic have an effect on life sciences?

BOGOTA, Colombia – The world is still reeling from President Barack Obama's historic announcement that the U.S. and Cuba would re-establish diplomatic relations that had been frozen since Washington imposed the 1960 embargo on the Caribbean island. Read More

Molecule found in lung cancer cells could be new target

LONDON – Scientists reported that they have found an ideal drug target that could lead to a treatment for lung cancer. The study, by an international team of researchers, identified a molecule that is found in lung cancer cells but not in normal lung tissue. Read More

Sciclone inks two-drug cardiovascular deal with Medicines for $50.5M

SHANGHAI – Sciclone Pharmaceuticals Inc. has had a pretty good year. The company continues to grow in the double digits and has hit revenue expectations for several quarters, helping to push stock prices to a rosy $8 to $9 range from a depressed low of $4 last year. Read More

Open 'Forum': Phase III could affirm worth of extra drug in Vanda/Novartis settlement

As the smoke clears from the resolution of Vanda Pharmaceuticals Inc.'s tussle with Novartis AG over the approved but weak-selling schizophrenia drug Fanapt (iloperidone), investors are turning their eyes toward AQW051, the phase II alpha-7 nicotinic acetylcholine receptor partial agonist that Vanda gained – along with a $25 million equity investment – in its settlement with the pharma giant. Read More

Pharma: Other news to note

Galderma Laboratories L.P., of Fort Worth, Texas, said the FDA approved Soolantra (ivermectin) Cream, 1 percent, for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe